AM

Adel Moussa

AP Atea Pharmaceuticals: 6 patents #1 of 2Top 50%
IP Idenix Pharmaceuticals: 3 patents #2 of 18Top 15%
📍 Calgary, CA: #6 of 737 inventorsTop 1%
Overall (2020): #12,318 of 565,922Top 3%
9
Patents 2020

Issued Patents 2020

Showing 1–9 of 9 patents

Patent #TitleCo-InventorsDate
10875885 β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment Jean-Pierre Sommadossi 2020-12-29
10874687 Highly active compounds against COVID-19 Jean-Pierre Sommadossi 2020-12-29
10870672 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Jean-Pierre Sommadossi 2020-12-22
10870673 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Jean-Pierre Sommadossi 2020-12-22
10815266 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment Jean-Pierre Sommadossi 2020-10-27
10723754 2′,4′-bridged nucleosides for HCV infection Benjamin Alexander Mayes, Alistair James Stewart 2020-07-28
10717758 D-amino acid compounds for liver disease Benjamin Alexander Mayes, Alistair James Stewart, David Dukhan 2020-07-21
10711029 Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection Jean-Pierre Sommadossi 2020-07-14
10683321 4′-or nucleosides for the treatment of HCV David Dukhan, Cyril B. Dousson, Benjamin Alexander Mayes, Alistair James Stewart 2020-06-16